- About Us
- Career Center
- Nano-Social Network
- Nano Consulting
- My Account
January 19th, 2005
Melbourne pharmaceutical developer Starpharma Holdings is on the verge of signing a strategic deal with Dow Chemical Company that would shore up its intellectual property position and give it access to an estimated 200 patents in the competitive field of nanotechnology.
The deal, which could be finalised by the end of next week, is expected to involve the transfer of Dow's extensive intellectual property portfolio into Starpharma's subsidiary Dendritic Nanotechnologies (DNT). In return, Dow will receive a 31 per cent equity stake in DNT.
|Related News Press|
Nanometrics Announces Upcoming Investor Events July 28th, 2015
Spintronics: Molecules stabilizing magnetism: Organic molecules fixing the magnetic orientation of a cobalt surface/ building block for a compact and low-cost storage technology/ publication in Nature Materials July 25th, 2015
An easy, scalable and direct method for synthesizing graphene in silicon microelectronics: Korean researchers grow 4-inch diameter, high-quality, multi-layer graphene on desired silicon substrates, an important step for harnessing graphene in commercial silicon microelectronics July 21st, 2015
Take a trip through the brain July 30th, 2015
Sol-gel capacitor dielectric offers record-high energy storage July 30th, 2015
Quantum networks: Back and forth are not equal distances! July 28th, 2015
Smarter window materials can control light and energy July 22nd, 2015